文拉法辛对脑卒中后抑郁患者的神经功能缺损及生活自理能力的影响

目的研究文拉法辛治疗脑卒中后抑郁患者时对神经功能缺损及生活自理能力的影响。方法选取2013-04—2014-12我科60例脑卒中后抑郁患者,随机分为对照组及研究组,对照组采用黛力新0.5mg/d治疗,研究组给予文拉法辛75mg/d治疗,此外,所有入选患者均接受相同的康复治疗和常规药物治疗,疗程共6周。在治疗前及治疗后第2、4、6周末,用汉密尔顿抑郁评定量表(HAMD)、焦虑量表(HAMA)和巴氏指数(BI)及美国国立卫生院卒中评分(NIHSS)评估疗效。结果 2组治疗后HAMD、HAMA得分较治疗前明显下降(P0.05)。治疗前BI及NIHSS评分差异均无统计学意义(P0.05),治疗第2周后NIHSS评分,治疗组较对照组明显降低(P0.05),而BI 2组无明显差异(P0.05);起病后6周,研究组BI较对照组升高(P0.01)。结论文拉法辛治疗脑卒中后抑郁的疗效可靠,并能改善患者神经功能及日常生活能力,促进肢体神经功能的康复,从而提高患者的生活质量。

The effects of Venlafaxine on neurological deficits and self-caring ability of daily life in patients with post-stroke depression

Objective To study the effects of Venlafaxine on neurological deficit and self-caring ability of daily life in pa‐tients with post-stroke depression (PCD) .Methods Sixty PSD in-patients treated by conventional therapy were consecutively enrolled in this randomized and open-label study and were divided into study group in which cases received 75 mg/d Venlafax‐ine and control group in which cases were given 0 .5 mg/d Deanxit for six weeks .Then we used Hamilton Depression Rating Scale (HAMD) ,Hamilton Anxiety Rating Scale (HAMA) ,Barthel Index (BI) and the National Institutes of Health Stroke American scores (NIHSS) to assess clinical efficacy of each group before treatment and at the two ,four and six weeks after treatment .Results After treatment ,HAMD and HAMA scores of the two groups were significantly decreased (P<0.05) . The BI and NIHSS scores showed no statistical differences before treatment (P>0.05) ,while NIHSS scores but not BI scores in the study group were significantly lower than those in the control group at the two weeks after treatment (P<0.05) .At the six weeks ,the study group had higher BI scores (P<0.01) .Conclusion Venlafaxine has a reliable effect on post-stroke depression ,which can improve the neurological deficits and self-caring ability of daily life and can promote physical recovery of neurological function so as to improve the quality of life .